

#60

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KJETIL TASKÉN et al

Appln. No.: 09/428, 158

Filed: October 28, 1999

For: USE OF IMMUNOMODULATING AGENTS



Group Art Unit: 1623

Examiner: Unknown

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 which the Examiner may deem relevant to patentability of the claims of the above-identified application.

A copy of the listed documents are submitted herewith.

The present Information Disclosure Statement is being filed before three months from the application's filing date, and before the mailing date of the first Office Action on the merits, therefore no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed document is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to

**INFORMATION DISCLOSURE STATEMENT**  
**U.S. Appln. No. 09/428,458**

antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



\_\_\_\_\_  
Gordon Kit  
Registration No. 30,764

**SUGHRUE, MION, ZINN,**  
**MACPEAK & SEAS, PLLC**  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: January 24, 2000